Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2412-2421

  Sharma, Arati ^a   Trivedi, Nishit R ^a   Zimmerman, Melissa A ^a   Tuveson, David A ^c   Smith, Charles D ^a   Robertson, Gavin P ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Foreman Foundation for Melanoma Research   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; SMALL INTERFERING RNA; SORAFENIB; VASCULOTROPIN; BENZENESULFONIC ACID DERIVATIVE; BRAF PROTEIN, HUMAN; PYRIDINE DERIVATIVE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; CELL GROWTH; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SECRETION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; APOPTOSIS; BENZENESULFONATES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 16844362816     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2423     Document Type: Article

References (44)

1. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999;9:51-8.
2. Serrone L, Zeuli M, Sega FM, et al. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19:21-34.
3. Atkins JH, Gershell LJ. Selective anticancer drugs. Nat Rev Drug Discov 2002;1:491-2.
4. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
6. Gorden A, Osman I, Gai W, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003;63:3955-7.
7. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
8. Uribe P, Wistuba II, Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 2003;25:365-70.
9. Sasaki Y, Niu C, Makino R, et al. BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 2004;123:177-83.
10. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40.
11. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
12. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-32.
13. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 2003;4:95-8.
14. Bollag G, Freeman S, Lyons JF, et al. Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 2003;4:1436-41.
15. Sumimoto H, Miyagishi M, Miyoshi H, et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004;23:6031-9.
16. Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal 2003;15:463-9.
17. Chang F, Steelman LS, Shelton JG, et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 2003;22:469-80.
18. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
19. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003;121:1160-2.
20. Lang J, Boxer M, MacKie R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat 2003;21:327-30.
21. Laud K, Kannengiesser C, Avril MF, et al. BRAF as a melanoma susceptibility candidate gene? Cancer Res 2003;63:3061-5.
22. Meyer P, Klaes R, Schmitt C, et al. Exclusion of BRAFV599E as a melanoma susceptibility mutation. Int J Cancer 2003;106:78-80.
23. Miller CJ, Cheung M, Sharma A, et al. Method of mutation analysis may contribute to discrepancies in reports of BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 2004;123:990-2.
24. Tsao H, Goel V, Wu H, et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122:337-41.
25. Krasilnikov M, Ivanov VN, Dong J, et al. ERK and P13K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 2003;22:4092-101.
26. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64:7002-10.
27. Hingorani SR, Jacobetz MA, Robertson GP, et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-202.
28. Stahl JM, Cheung M, Sharma A, et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63:2881-90.
29. Bankston D, Dumas J, Natero R, et al. A scaleable synthesis of BAY 43-9006: a potent Raf kinase inhibitor for the treatment of cancer. Organic Process Res Dev 2002;6:777-81.
30. Robertson GP, Furnari FB, Miele ME, et al. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci U S A 1998;95:9418-23.
31. Lowinger TB, Riedl B, Dumas J, et al. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002;8:2269-78.
32. Lyons JF, Wilhelm S, Hibner B, et al. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-25.
33. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
34. Kranenburg O, Gebbink MF, Voest EE. Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta 2004;1654:23-37.
35. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29:3-9.
36. Wojnowski L, Zimmer AM, Beck TW, et al. Endothelial apoptosis in Braf-deficient mice. Nat Genet 1997;16:293-7.
37. Heidenreich R, Machein M, Nicolaus A, et al. Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. Int J Cancer 2004;111:348-57.
38. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
39. Ahmad T, Marais R, Pyle L, et al. BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience. Proc Am Soc Clin Oncol 2004;23:708.
40. Flaherty K, Brose MS, Schlichter L, et al. Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proc Am Soc Clin Oncol 2004;23:708.
41. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997;94:2031-5.
42. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62:6158-64.
43. Hale JT, Bigelow JC, Mathews LA, et al. Analytical and pharmacokinetic studies with 5-chloro-2′-deoxycytidine. Biochem Pharm 2002;64:1493-502.
44. Kimura Y, Aoki J, Kohno M, et al. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 2002;49:322-8.